// App-Quantinova.ai

526 : Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

Researchers

Presenter

  • Guy Heinrich Maria Jerusalem

Principal Investigators

  • Toshinari Yamashita

  • Sara A. Hurvitz

  • Shanu Modi

  • Fabrice Andre

  • Ian E. Krop

  • Xavier Gonzalez

  • Peter S. Hall

  • Benoit You

  • Cristina Saura

  • Sung-Bae Kim

  • Cynthia R. C. Osborne

  • Yasuaki Sagara

  • Eriko Tokunaga

  • Yali Liu

  • Jillian Cathcart

  • Caleb C. Lee

  • Christophe Perrin

Medical Centers

  • Centre Hospitalier Universitaire du Sart Tilman Liege and Liege University, Liege, Belgium

  • Samsung Medical Center, Seoul, Korea

  • Kanagawa Cancer Center, Yokohama, Japan

  • University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Memorial Sloan Kettering Cancer Center, New York, NY, Gustave Roussy, Université Paris-Sud, Villejuif, France

  • Dana-Farber Cancer Institute, Boston, MA

  • Instituto Oncológico Dr Rosell, Hospital General De Catalunya, SOLTI, Barcelona, Spain

  • Edinburgh Cancer Research Center, University of Edinburgh, Edinburgh, United Kingdom

  • Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • US Oncology Research, McKesson Specialty Health, The Woodlands, TX; Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX

  • Hakuaikai Medical Corporation Sagara Hospital, Kagoshima City, Japan

  • National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

  • Daiichi Sankyo, Inc, Basking Ridge, NJ, Centre Eugène Marquis, Rennes, France

Locations

  • Belgium

  • Japan

  • France

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Brain metastasis

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03248492

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved